文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

高强度聚焦超声辅助肝切除术(HIFU-AR)减少需行肝切除术的肝转移患者术中出血的疗效:随机对照试验研究方案

Efficacy of high-intensity focused ultrasound-assisted hepatic resection (HIFU-AR) on blood loss reduction in patients with liver metastases requiring hepatectomy: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-02-06

本研究为前瞻性、单中心、1:1随机、开放标签II期研究,纳入需切除≥2个肝段的结直肠肝转移患者,评估HIFU辅助肝切除术(HIFU-AR)能否减少出血。主要终点为按肝切面面积归一化的出血量(mL/cm²)。假设对照组出血量为7.6 ± 3.7 mL/cm²,每组需21例随机患者,检验效能85%,双侧显著性水平0.05。

要点

  • HIFU-AR通过术中高强度聚焦超声探头以凝固性坏死破坏组织,旨在减少肝切除时出血。
  • 主要终点为归一化出血量(mL/cm²肝切面),对照组假设为7.6 ± 3.7 mL/cm²。
  • 每组需21例随机患者,按外科医生分层随机,入组期24个月。

关键数值与推荐

  • 主要终点为归一化出血量,单位为mL/cm²肝切面面积。
  • 次要终点包括总出血量、切开时间、每平方厘米肝面积切开时间、止血时间、肝切面夹密度、Pringle手法使用率与持续时间、需输血患者比例、住院时长、并发症、切缘阳性患者及局部复发。
  • 对照组假设出血量为7.6 ± 3.7 mL/cm²。
  • 每组需21例随机患者,另最多可额外入组8例,入组期24个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver resection is the only potentially curative treatment for colorectal liver metastases (LM). It is considered a safe procedure, but is often associated with blood loss during liver transection. Blood transfusions are frequently needed, but they are associated with increased morbidity and risk of recurrence. Many surgical devices have been developed to decrease blood loss. However, none of them has proven superior to the standard crushing technique. We developed a new, powerful intra-operative high-intensity focused ultrasound (HIFU) transducer which destroys tissue by coagulative necrosis. We aim to evaluate whether HIFU-assisted liver resection (HIFU-AR) results in reduced blood loss. METHODS: This is a prospective, single-centre, randomized (1:1 ratio), comparative, open-label phase II study. Patients with LM requiring a hepatectomy for ≥ 2 segments will be included. Patients with cirrhosis or sinusoidal obstruction syndrome with portal hypertension will be excluded. The primary endpoint is normalized blood loss in millilitres per square centimetre of liver section plane. Secondary endpoints are: total blood loss, transection time, transection time per square centimetre of liver area, haemostasis time, clip density on the liver section area, rate and duration of the Pringle manœuvre, rate of patients needing a blood transfusion, length of hospital stay, morbidity, patients with positive resection margin, and local recurrence. Assuming a blood loss of 7.6 ± 3.7 mL/cm2 among controls, the study will have 85% power to detect a twofold decrease of blood loss in the experimental arm, using a Wilcoxon (Mann-Whitney) rank-sum test with a 0.05 two-sided significance level. Twenty-one randomized patients per arm are required. Considering the risk of contraindications at surgery, up to eight patients may be enrolled in addition to the 42 planned, with an enrolment period of 24 months. Randomization will be stratified by surgeon. DISCUSSION: We previously demonstrated the safety and efficacy of intra-operative HIFU in patients operated on for LM. We also demonstrated the efficacy of HIFU-AR in a preclinical study. Participants in the HIFU-AR group of this randomized trial can expect to benefit from reduced blood loss and decreased ischemia of liver parenchyma. TRIAL REGISTRATION: Clinicaltrial.gov, NCT02728167 . Registered on 22 March 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dupré A, Pérol D, Blanc E, et al. Efficacy of high-intensity focused ultrasound-assisted hepatic resection (HIFU-AR) on blood loss reduction in patients with liver metastases requiring hepatectomy: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28166812. doi:10.1186/s13063-017-1801-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。